Severe cutaneous eruptions following the topical use of preparations containing bufexamac: Is it time to reconsider its registration in Australia?

AUSTRALASIAN JOURNAL OF DERMATOLOGY(2019)

引用 6|浏览2
暂无评分
摘要
Despite being a well-recognised cause of allergic contact dermatitis with an embargo in many countries around the world, bufexamac is available over the counter in topical preparations in Australia. We present a series of patients who developed severe cutaneous eruptions after the topical application of bufexamac containing preparations to highlight the potential risks of this medication, as well as advocate for the reconsideration of its registration by the Therapeutic Goods Administration in Australia.
更多
查看译文
关键词
bufexamac,contact dermatitis,drug reaction,non-steroidal anti-inflammatory agents,patch tests
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要